Vice Presidents

Partner, Ausvic Capital Limited Investment

Graduated from Renmin University of China, partner of Ausvic Capital, Honorary President of New Territories West Residents Association, Executive Vice President of Hong Kong Hunan Youth Association, member of the 28th and 29th Board of Directors of the Hong Kong Association of Youth. Mainly responsible for investment and collaboration in the fields of blockchain, quantum technology, space technology, and longevity.

Chief Executive Officer, Cameron Pace China Limited

Gordon Cheng is the CEO of Cameron Pace Group China (CPGC), the exclusive joint venture set up with famous film industry leader and scientist James Cameron in China, focusing on film and media technologies, especially on 3D areas. In addition to daily operations, Mr. Cheng is also driving the R&D and strategic developments relating to artificial intelligence, advanced 3D display and other cutting edge visual technologies. Mr. Cheng has been the senior management/employee, Board member and advisor for various global and Chinese listed companies across different industries involving finance (JPMorgan, Credit Suisse and Deutsche Bank), natural resources (China Molybdenum), semiconductor (Vimicro), infrastructure/real estate (LaSalle Fund). Mr. Cheng has been active as the Board member and senior advisor on various global initiatives on climate changes and natural conservation, including African Wildlife Foundation and UNIDO.

Founder & CEO, Ryoden Medical Holdings & Incando Therapeutics Group

Dr Hu is a translational biomedical engineer with a strong background in business development. His passion is in building a vibrant biotech ecosystem through bridging stakeholders across relevant sectors. He heads Ryoden Medical where he oversees healthcare and biotech venture investments for his family office. He co-founded Incando Therapeutics and Cere Ventures to bring brain- and healthy aging-related developments to the market. Dr Hu currently serves as Chair of Biomedical Engineering Departmental Advisory Council and Adjunct Professor in Biomedical Sciences at the City University of Hong Kong, as well as board member or steering committee member to several charities, think-tanks, universities and government committees in Hong Kong, such as the Hong Kong Biotechnology Organization, the Asian Fund for Cancer Research Limited, the Hong Kong Professionals and Senior Executives Association, the Hong Kong Trade & Development Council, and the Hong Kong Innovation & Technology Commission. Dr Hu received his PhD in Tissue Engineering from Johns Hopkins University, BS in Bioengineering from the University of California, Berkeley, and has been awarded the Hong Kong-Zhuhai-Macau Greater Bay Area Most Talented Young Entrepreneur Award with the Best Technology Innovation Distinction in 2023.

Founder &CEO, Quantum Life Limited; Managing Director, HK Longevity Medical Centre

Dr. Christine Yuan HUANG is the Founder and CEO of QuantumLife. Dr. Huang is also the Technology Transfer Director of Hong Kong Quantum AI Lab, and Managing Director of HK Longevity Medical Centre, focusing on providing end-to-end precision longevity medical technology solutions to improve health-span. Dr. Huang has vast experience in the biotechnology and longevity field and shares her professional insights as a Venture Partner of LongeVC.

Dr. Huang was selected as one of Forbes China 2020 “30 Under 30 (Healthcare and Science)” for her development of cancer liquid biopsy technology, and she was awarded as the “Pioneer of Genome Technology ”in 2025. In 2022, she was elected as a Fellow of the Royal Society of Medicine in the UK, and in 2024, she became a Fellow of the European Society of Preventive Medicine. She is also a member of the Advisory Board of Wing Wah Charity Foundation Hong Kong, and a columnist of Forbes China. Dr. Huang was elected as a Fellow of Guangzhou Youth Federation in November 2022. Dr. Huang obtained Doctor of Medicine from the Southern Medical University and Master of Public Health from the University of Hong Kong, Li Ka Shing Faculty of Medicine. Now she is also an Honorary Senior Research Associate at the University of Hong Kong.

Co-founder, Silver Dart Capital Partner (Healthcare Investments), Value Partners Group

Dr. Chuen Yan Leung is currently Partner (Healthcare Investments) at Value Partners Group, one of Asia’s largest independent asset management firms offering world-class investment services and products for institutional and individual clients globally. He has 14 years of experience in the healthcare ecosystem from R&D, biotechnology start-ups, venture capital, and private equity. Previously Dr. Leung was a co-founder of Silver Dart Capital, a boutique healthcare private equity firm and a private equity vice president at EQT Group, a Swedish global investment organization with EUR 210bn assets under management as of 2023. He has previously held roles such as Vice President at Aeneas Capital and Lead Scientist at Procella Therapeutics. Dr. Leung is currently the Vice President of the Hong Kong Biotechnology Organization, and a member of the Shanghai Pudong Chinese People’s Political Consultative Conference. Dr. Leung received his PhD in Stem Cell Biology from the University of Cambridge, and BSc in Biochemistry from Imperial College London.

Managing Director, CR CP Life Science Fund

Mr. Liu is now the Managing Director of the CR CP Life Science Fund, whose shareholders, CR Group and CP Group are on the Fortune Global 500 List. Before that, Mr. Liu was the Business Director of the Strategic Management Department at CR Group, responsible for strategic research and project investment in life science and technology; and as Senior Director of China Resources Pharmaceutical Group Co., Ltd. (HK: 03320), responsible for business development and international cooperation. He has also served as the Senior Director of China Resources Pharmaceutical Business Group, the General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., the Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and the COO of Zhoulin Bio-spectrum Technology Co., Ltd. Prior to 2004, Mr. Liu was a pharmacy manager at CVS Group in the United States, and worked at the New York Healthcare Group as a clinical pharmacist.

Managing Director and Head of Healthcare, VMS Group; Investment Partner, Panacea Venture

Andrew Ng is a Managing Director and Head of Healthcare of VMS Group and an Investment Partner of Panacea Venture. He has over 13 years of experience in the healthcare industry across Asia and the US. Andrew has established the healthcare practice of VMS Group in 2017 and led multiple growth-stage investments for VMS across the therapeutics, diagnostics, medical device and CRO/CDMO verticals. He has also served as an Investment Partner of Panacea Venture, a global healthcare venture capital firm, since 2021.

Prior to that, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.

Andrew has been on the board of multiple companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and CXO industries. These companies include New Horizon Health, Chime Biologics, Jade Biomedical, SyMap Medical, Yizun Biomedicine and Profusa.

Andrew received an MBA from INSEAD, a M.Eng. degree and a BS degree in Operations Research & Engineering from Cornell University.

Former President, Rotary Club Kowloon Golden Mile

Dr. Maki Wan is a seasoned professional in corporate strategic planning and business development, with over 20 years of service at Mitsubishi Corporation, the largest Japanese conglomerate. Her extensive experience includes a pivotal role at Mitsubishi’s headquarters in Tokyo from 2011 to 2015, when she managed the Group Chairman’s external relations. In this capacity, Dr. Wan enhanced the company’s international presence by supporting Mitsubishi at high-profile global conferences, including the World Economic Forum, and facilitating meetings between senior executives and national leaders.

Currently serving as Mitsubishi Deputy General Manager in Hong Kong, Dr. Wan oversees strategic planning and business development.

Born in China and raised in Japan, Dr. Wan has a rich multicultural background. She pursued her academic journey in Japan, France, and Hong Kong, ultimately earning a Ph.D. in French Literature and Cultural Studies from the Chinese University of Hong Kong.

Beyond her corporate achievements, Dr. Wan is involved in philanthropy. As the Past President of the Rotary Club Kowloon Golden Mile, the largest Rotary Club in Hong Kong, she has led numerous fundraising initiatives. Additionally, she serves as an advisory board member for the Asian Fund for Cancer Research and is Vice President of BIOHK.

Associate, Philip K.H. Wong, Kennedy Y.H. Wong & Co

30th Board of Directors / Deputy Secretary of Hong Kong United Youth Association

Founding and Executive Partner, CDF Capital Orion Fund and Orion Technology Fund

He has been the head of a family office in Hong Kong for many years, participated in hundreds of millions of dollars of overseas M&A projects and the acquisition and management of Hong Kong main board listed companies, and managed the family office’s overseas investment and global asset allocation with many internationally renowned investment banks. The M&A projects he has participated in include Four Seasons Hotel, golf courses, internationally renowned beverage companies, etc.